SynthesisLipids in health and disease2019
Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis.
Synthesis in Lipids in health and disease, 2019. The graph read 3 numbers from its abstract, feeding 2 cells of the map, but none could be read as for or against, so it casts no vote. An erratum has been issued. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
Similar reduced were observed for CV hospitalizations - they were reduced in statin users in both EF groups (HR 0.80 95CI: 0.64-0.99, p = 0.04, and HR 0.76 95% CI: 0.61-0.93, p = 0.009, respectively, Fig. 6 ).
Compared with non-statin use, statin use was associated with lower risk of all-cause mortality (HR 0.77, 95% confidence interval [CI], 0.72-0.83, P < 0.0001, I CONCLUSIONS: In conclusion, statins may have a beneficial effect on CV outcomes irrespective of HF etiology and LVEF level.
Compared with non-statin users, statin users showed a lower risk of all-cause mortality (HR 0.77, 95% confidence interval [CI], 0.72-0.83, P < 0.0001, I 2 = 63%, Fig. 2 ), CV mortality (HR 0.82, 95% Cl: 0.76-0.88, P < 0.000, I 2 = 63%) and CV hospitalization (HR 0.78, 95% Cl: 0.69-0.89, P = 0.0003, I 2 = 36%, Fig. 3 a and b).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Statins×adverse events & safety
No readable resultOpen on the map →What to test next →11 readable studies in this cell: 3 favour the treatment, 7 find no difference, 1 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
Statins×all-cause mortality
No readable resultOpen on the map →What to test next →14 readable studies in this cell: 3 favour the treatment, 9 find no difference, 2 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.Nutrients · 2020 · on this mapPooled it
- Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial.Frontiers in cardiovascular medicine · 2026Trial
- Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial.Clinical cardiology · 2022Trial
- The prognostic value of secreted frizzled-related protein 2 in elderly patients with heart failure: a single-center retrospective study.Scientific reports · 2025Article
- Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease.Clinical and molecular hepatology · 2025Article
- Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Cardiometabolic Dysregulation and Heart Failure.Reviews in cardiovascular medicine · 2025Review
- Impact of statin use on short- and long-term outcomes in patients with sepsis-induced myocardial injury: insights from the MIMIC-IV database.Frontiers in pharmacology · 2025Article
- Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study.PloS one · 2025Article
- Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction.Journal of clinical medicine · 2024Article
- Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives.International journal of molecular sciences · 2024Review
- Effects of Administration and Intensity of Statins on Mortality in Patients Undergoing Hemodialysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Management of dyslipidemia in special groups.Indian heart journal · 2024Review
- Residual cardiovascular disease risk in heart failure patients. What is the real role of lipid-lowering therapy?Archives of medical science : AMS · 2024Article
- Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- The impact of statin use on short-term and long-term mortality in patients with heart failure.Frontiers in pharmacology · 2024Article
- Correlation between Statin Solubility and Mortality in Patients on Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2023Article
- Lower low density lipoprotein cholesterol associates to higher mortality in non-diabetic heart failure patients.International journal of cardiology. Cardiovascular risk and prevention · 2023Article
- Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease.World journal of cardiology · 2023Review
- Impact of Statin Therapy in Heart Failure Patients: Results of a Large Real-World Experience.JACC. Advances · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 7 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundThe role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins' prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF.
methodsWe searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2009 PRISMA statement for reporting and applied independent extraction by multiple observers. Meta-analyses of hazard ratios (HRs) of effects of statins on clinical outcomes used generic inverse variance method and random model effects. Clinical outcomes were all-cause mortality, cardiovascular (CV) mortality and CV hospitalization.
resultsFinally we included 17 studies (n = 88,100; 2 RCTs and 15 cohorts) comparing statin vs non-statin users (mean follow-up 36 months). Compared with non-statin use, statin use was associated with lower risk of all-cause mortality (HR 0.77, 95% confidence interval [CI], 0.72-0.83, P < 0.0001, I
conclusionsIn conclusion, statins may have a beneficial effect on CV outcomes irrespective of HF etiology and LVEF level. Lipophilic statins seem to be much more favorable for patients with heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.